Table 3.
OR (95%CI) for the associations between seropositivity for anti-Parietal cell antibodies and esophageal and gastric cancers in the Linxian General Population Nutrition Intervention Trial, stratified by sex and age subgroups
| Group | Cancer type | Case No. | Seropositivity for anti-Parietal cell antibodies (>10 units) |
|
|---|---|---|---|---|
| n (%) | OR (95%CI) | |||
| Alla | Control | 400 | 69 (17.25) | - |
| UGI cancer | 500 | 68(13.60) | 0.71(0.48-1.05) | |
| ESCC | 100 | 19 (19.00) | 1.05(0.58-1.88) | |
| GCA | 200 | 20 (10.00) | 0.42(0.24-0.75) | |
| GNCA | 200 | 29 (14.50) | 0.82(0.50-1.36) | |
| Femalesb | Control | 229 | 44 (19.21) | - |
| UGI cancer | 204 | 29(14.22) | 0.59(0.34-1.02) | |
| ESCC | 54 | 13(24.07) | 1.23(0.59-2.55) | |
| GCA | 83 | 6 (7.23) | 0.22(0.08-0.59) | |
| GNCA | 67 | 10 (14.93) | 0.60(0.27-1.34) | |
| Malesb | Control | 171 | 25 (14.62) | - |
| UGI cancer | 296 | 39(13.18) | 0.90(0.50-1.60) | |
| ESCC | 46 | 6 (13.04) | 0.85(0.31-2.30) | |
| GCA | 117 | 14 (11.97) | 0.71(0.33-1.52) | |
| GNCA | 133 | 19 (14.29) | 1.08(0.53-2.17) | |
| <55 yearsc | Control | 258 | 43 (16.67) | - |
| UGI cancer | 239 | 35(14.64) | 0.75(0.45-1.25) | |
| ESCC | 58 | 11 (18.97) | 1.00(0.46-2.18) | |
| GCA | 103 | 12 (11.65) | 0.43(0.20-0.93) | |
| GNCA | 78 | 12 (15.38) | 0.90(0.44-1.87) | |
| ≥55 yearsc | Control | 142 | 26 (18.31) | - |
| UGI cancer | 261 | 33(12.64) | 0.62(0.35-1.12) | |
| ESCC | 42 | 8 (19.05) | 1.17(0.47-2.95) | |
| GCA | 97 | 8 (8.25) | 0.34(0.14-0.86) | |
| GNCA | 122 | 17 (13.93) | 0.66(0.33-1.35) | |
Note: ESCC, esophageal squamous cell carcinoma; GCA, gastric cardia adenocarcinoma; GNCA, gastric non-cardia adenocarcinoma; UGI, upper gastrointestinal cancer; Numbers in bold mean that the P value was less than 0.05; We found no evidence for a statistically significant interaction between APCA seropositivity and sex or age group (p>0.05).
adjusted for age, sex, tobacco smoking, alcohol drinking, body mass index, family history of UGI cancer, H. pylori CagA sero-positivity, and ratio of PG I/II.
adjusted for age, tobacco smoking, alcohol drinking, body mass index, family history of UGI cancer, H. pylori CagA sero-positivity, and ratio of PG I/II.
adjusted for sex, tobacco smoking, alcohol drinking, body mass index, family history of UGI cancer, H. pylori CagA sero-positivity, and ratio of PG I/II.